Chemotherapy and Interactions with Combination Antiretroviral Therapy

  • Nicolas MounierEmail author
  • Michelle A. Rudek


Combination antiretroviral therapy (cART) has markedly reduced morbidity and mortality of AIDS-related complications in patients with HIV. Despite the overall success of cART, hematological malignancies remain a common source of morbidity and mortality. In this chapter, we discuss the management of cART in relation to antineoplastic agents and potential pharmacological interactions between cART and antineoplastic agents and consider how to combine cART and antineoplastic agents in patients with HIV.


Vinca Alkaloid Drug Interaction Potential CYP450 Isozyme cART Regimen Unconjugated Hyperbilirubinemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at Accessed 27 Nov 2014.
  2. 2.
    Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS. 2010;24:851–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92:191–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251–62.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004;125:455–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:422–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30:4117–23.Google Scholar
  9. 9.
    Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100:1984–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–16.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Martis N, Mounier N. Hodgkin lymphoma in patients with HIV infection: a review. Curr Hematol Malig Rep. 2012;7:228–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Ezzat HM, Cheung MC, Hicks LK, et al. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma. 2012;53:2390–6.Google Scholar
  14. 14.
    Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS. 2010;24:2408–12.Google Scholar
  15. 15.
    Cianfrocca M, Lee S, Von Roenn J, et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol. 2011;68:827–33.Google Scholar
  16. 16.
    Rudek MA, Chang CY, Steadman K, et al. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemother Pharmacol. 2014;73:729–36.Google Scholar
  17. 17.
    Koon HB, Krown SE, Lee JY, et al. Phase II trial of imatinib in AIDS-associated Kaposi’s sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol. 2014;32:402–8.Google Scholar
  18. 18.
    Rudek MA, Moore PC, Mitsuyasu RT, et al. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014;120:1194–1202.Google Scholar
  19. 19.
    Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib–an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. Drug Metab Dispos. 2013;41:1843–51.Google Scholar
  20. 20.
    Pillai VC, Parise RA, Christner SM, et al. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib–a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer. J Clin Pharmacol. 2014;54:1272–9.Google Scholar
  21. 21.
    Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12:905–12.Google Scholar
  22. 22.
    Beumer JH, Venkataramanan R, Rudek MA. Pharmacotherapy in cancer patients with HIV/AIDS. Clin Pharmacol Ther. 2014;95:370–2.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Onco-HematologyArchet HospitalNiceFrance
  2. 2.The Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations